Evcolek (chlorophyllipt thick extract) suppositories 0.05 g. №5

Description

Evcolek Composition
active substance: thick extract of chlorophyllipt;

1 suppository contains chlorophyllipt extract thick (Eucalypti) (1: 15.3-10.76: 1) (extractant ethanol 93-96%) (calculated on dry matter) 0.05 g (50 mg);

Evcolek excipients:

polysorbate, solid fat.

Evcolek Dosage form.

Suppositories.

Basic physical and chemical properties: suppositories of dark green color, bullet-shaped. The presence of white plaque on the surface of the suppository is allowed.

Pharmacotherapeutic group. Antimicrobial and antiseptic agents used in gynecology. ATX code G01A X.

Pharmacological properties

Pharmacodynamics.

The active ingredient of the drug is thick chlorophyllipt extract. Chlorophyllipt extract has a stimulating effect on the receptors of the mucous membranes, and also has local anti-inflammatory and antiseptic activity.

The drug has antibacterial (bacteriostatic and bactericidal) activity against staphylococci.

Pharmacokinetics.

Not described.

Clinical characteristics.

Indications
Treatment of infectious and inflammatory processes of female genital organs (colpitis, vaginitis, vulvovaginitis) and intestines caused by antibiotic-resistant strains of staphylococci.

Contraindications
Hypersensitivity to chlorophyllipt or other components of the drug.

Interaction with other medicinal products and other types of interactions.

There are no data on drug interactions.

Application features
Before starting treatment, you should consult your doctor.

After taking the first suppository, you should pause for 6 to 8 hours.

Course treatment with the drug is possible after confirming the absence of an allergic reaction to the thick chlorophyllipt extract (the likelihood of edema of the lips, nasal mucosa, pharynx and other allergic reactions). If any of the above symptoms appear, the use of the drug should be discontinued and a doctor should be consulted.

Application during pregnancy or lactation.

The efficacy and safety when using the drug during pregnancy or lactation have not been studied, so the drug should not be used in this category of patients.

The ability to influence the reaction rate when driving or driving other mechanisms.

There is no data.